Envarsus PA (Tacrolimus Prolonged-Release Tablets) – Uses, Dosing, Side Effects, and Important Warnings

Envarsus PA is a prescription immunosuppressant medication that contains tacrolimus in a prolonged-release tablet. It is used in adult kidney or liver transplant patients to help prevent organ rejection when used with other immunosuppressive medications.

Tacrolimus helps reduce immune system activity so the body is less likely to attack a transplanted organ. Because dosing must be closely monitored, Envarsus PA should only be prescribed and managed by healthcare providers experienced in transplant medicine.

What Envarsus PA Is Used For

Envarsus PA is indicated for the prevention of organ rejection in adult patients who have received:

• A kidney transplant
• A liver transplant

It is used in combination with other immunosuppressants. Envarsus PA is not authorized for pediatric use in Canada.

How Envarsus PA Works

Tacrolimus is a calcineurin inhibitor. It works by suppressing T-cell activation, which plays a major role in transplant rejection.

By reducing immune activity, Envarsus PA helps protect the transplanted organ from immune attack. However, this also increases the risk of infections and certain cancers, so careful monitoring is required.

Available Strengths

• 0.75 mg prolonged-release tablets
• 1 mg prolonged-release tablets
• 4 mg prolonged-release tablets

The tablets should be swallowed whole and should not be chewed, divided, or crushed.

Envarsus XR in the U.S. vs Envarsus PA in Canada

Patients in the United States may recognize this medication as Envarsus XR, while in Canada it is called Envarsus PA.

The difference is mainly the naming:

• In the United States, the product is commonly known as Envarsus XR.
• In Canada, the product is marketed as Envarsus PA.
• Both refer to tacrolimus prolonged-release / extended-release tablet therapy.

The letters reflect different market naming conventions. “XR” is commonly used in the U.S. to mean extended release, while “PA” in Canada refers to prolonged-action/prolonged-release labeling.

Patients should never switch between tacrolimus products without transplant specialist supervision. Even small formulation changes can affect tacrolimus blood levels, which may increase the risk of rejection or toxicity.

How to Take Envarsus PA

• Take once daily at the same time each day, preferably in the morning.
• Take consistently either with or without food as directed.
• It is generally recommended to take it at least 1 hour before a meal or 2 hours after a meal.
• Avoid high-fat meals around dosing unless your transplant team instructs otherwise.
• Swallow tablets whole with fluid, preferably water.

Avoid grapefruit, grapefruit juice, and alcohol while taking Envarsus PA.

Typical Dosing

New kidney transplant patients

• Recommended initial dose: 0.17 mg/kg once daily
• Typical trough levels: 7–20 ng/mL during days 1–90, then 5–15 ng/mL during months 4–12

New liver transplant patients

• Recommended initial dose: 0.11–0.13 mg/kg once daily
• Typical trough levels: 5–20 ng/mL during days 1–60, then 5–15 ng/mL during months 3–12

Conversion from immediate-release tacrolimus

• Stable kidney or liver transplant patients may be converted from immediate-release tacrolimus to Envarsus PA under specialist supervision.
• A common conversion is 1 mg immediate-release tacrolimus to 0.7 mg Envarsus PA total daily dose.
• Black African American patients may require a different conversion ratio, such as 1 mg to 0.85 mg Envarsus PA.

Tacrolimus blood trough levels must be checked before and after conversion.

Missed Dose

• Take a missed dose as soon as possible on the same day.
• Do not take a double dose the next day.
• If you are unsure what to do, contact your transplant team.

Serious Warnings

Infection risk

Envarsus PA suppresses the immune system and can increase the risk of serious bacterial, viral, fungal, and opportunistic infections. Some infections may require hospitalization and can be life-threatening.

Cancer risk

Immunosuppressants such as tacrolimus can increase the risk of lymphoma and other cancers, especially skin cancer. Patients should limit sunlight and UV exposure, wear protective clothing, and use sunscreen.

Specialist prescribing only

Envarsus PA should only be prescribed by physicians experienced in immunosuppressive therapy and transplant management.

Common Side Effects

Common side effects reported with tacrolimus therapy include:

• Diarrhea
• Urinary tract infection
• Anemia
• High blood pressure
• Constipation
• Tremor
• Headache
• Increased blood creatinine
• High blood sugar or new-onset diabetes

Important Precautions

Kidney problems

Tacrolimus can cause kidney toxicity, especially when blood levels are too high or when combined with other kidney-stressing medications. Kidney function should be monitored regularly.

High potassium

Tacrolimus can increase potassium levels. Patients may need periodic blood tests, especially if taking ACE inhibitors, ARBs, potassium supplements, or potassium-sparing diuretics.

Neurologic effects

Tacrolimus may cause tremor, headache, numbness, confusion, seizures, or posterior reversible encephalopathy syndrome (PRES). New neurologic symptoms should be reported promptly.

Heart rhythm concerns

Tacrolimus may prolong the QT interval in some patients. Extra caution may be needed in patients with heart disease, low magnesium, low potassium, or medications that affect heart rhythm.

Diabetes risk

Tacrolimus can cause new-onset diabetes after transplant. Blood glucose monitoring may be needed, especially in higher-risk patients.

Drug and Food Interactions

Envarsus PA has many important interactions because tacrolimus is metabolized by CYP3A enzymes.

Medications or substances that may increase tacrolimus levels include:

• Azole antifungals such as ketoconazole, itraconazole, voriconazole, and fluconazole
• Macrolide antibiotics such as clarithromycin and erythromycin
• Calcium channel blockers such as diltiazem, verapamil, and nifedipine
• Protease inhibitors such as ritonavir
• Grapefruit and grapefruit juice

Medications or substances that may lower tacrolimus levels include:

• Rifampin and rifabutin
• Carbamazepine, phenytoin, and phenobarbital
• St. John’s Wort

Patients should never start or stop medications, supplements, or herbal products without checking with their transplant team.

Vaccines

Live vaccines should be avoided during treatment with Envarsus PA. Inactivated vaccines may be used when appropriate, but they may not work as well because of immunosuppression.

Pregnancy and Breastfeeding

Tacrolimus crosses the placenta and has been associated with risks such as prematurity, low birth weight, neonatal high potassium, and kidney problems. It should only be used during pregnancy if the benefit justifies the risk.

Tacrolimus is also excreted into breast milk. A healthcare provider should help decide whether to continue breastfeeding or continue treatment.

Storage

• Store between 15°C and 25°C.
• Keep tablets in the original bottle to protect from light.
• Keep out of reach of children.

Buying Envarsus PA from Canada

Transplant medications are long-term therapies, and out-of-pocket costs can become difficult for some U.S. patients. Some Americans compare Canadian pricing for brand name transplant medications when looking for lower-cost options.

Over The Border Meds is a Canadian prescription referral service that helps eligible patients access medications from Canada with a valid prescription. For Envarsus PA, it is especially important that the prescription clearly states the exact strength, daily dose, and formulation because tacrolimus products are not automatically interchangeable.

Learn more: Over The Border Meds

Disclaimer

This information is for educational purposes only and does not replace transplant specialist advice. Envarsus PA must be taken exactly as prescribed, with regular tacrolimus blood level monitoring. Never switch tacrolimus formulations without medical supervision.

Reference: Envarsus PA Product Monograph (Canada)

Envarsus XR / PA is taken once daily in the morning on an empty stomach, at least 1 hour before or 2 hours after eating, as prescribed by your doctor. Swallow the tablet whole with water and take it at the same time each day to maintain consistent levels in your body. Avoid grapefruit products, and always follow your healthcare provider’s instructions and regular blood monitoring.